SCHEMBL239104

SCHEMBL239104

CC1(C)OB(c2ccc(F)c(F)c2)OC1(C)C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPL P06858 13/20 0.56
LIPG Q9Y5X9 13/20 0.56
ROCK1 Q13464 1/20 0.46
EGFR P00533 1/20 0.43
CA1 P00915 3/20 0.41
CA2 P00918 3/20 0.41
CA9 Q16790 3/20 0.41
CA12 O43570 1/20 0.41
CA3 P07451 1/20 0.41
CA4 P22748 1/20 0.41
CA6 P23280 1/20 0.41
CA5A P35218 1/20 0.41
CA7 P43166 1/20 0.41
CA14 Q9ULX7 1/20 0.41
CA5B Q9Y2D0 1/20 0.41
F11 P03951 2/20 0.40
F2 P00734 1/20 0.38
PRSS1 P07477 1/20 0.38
PRSS2 P07478 1/20 0.38
PRSS3 P35030 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL59080 0.85 LPL (0.53) LPLLIPGROCK1CA1CA2
SCHEMBL20648243 0.85 LPL (0.53) LPLLIPGROCK1EGFRCA1
SCHEMBL14616470 0.85 LPL (0.53) LPLLIPGROCK1EGFRCA1
SCHEMBL31550445 0.85 LPL (0.53) LPLLIPGROCK1EGFRCA1
SCHEMBL17491867 0.85 LPL (0.53) LPLLIPGROCK1EGFRCA1
SCHEMBL2640296 0.85 LPL (0.53) LPLLIPGROCK1EGFRCA1
SCHEMBL17339031 0.85 LPL (0.53) LPLLIPGROCK1EGFRCA1
Ammonia Solution, Strong SCHEMBL18497260 0.83 LPL (0.51) LPLLIPGROCK1EGFRCA1
SCHEMBL2130844 0.83 LPL (0.51) LPLLIPGROCK1EGFRCA1
SCHEMBL12496719 0.83 LPL (0.51) LPLLIPGROCK1EGFRCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 US disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 US disclosed
US-20230285378-A1 Anti-Viral Compounds ABBVIE INC. (US) 2023-09-14 US disclosed
US-20230167088-A1 1-PYRAZINYLPYRAZOLYL-3-OXYALKYL ACIDS AND THEIR DERIVATIVES, AND THEIR USE FOR CONTROL OF UNDESIRED PLANT GROWTH BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 US disclosed
CN-115943143-A 1-pyrazinylpyrazolyl-3-oxyalkyl acids and derivatives thereof and their use for controlling undesired vegetation 拜耳公司 2023-04-07 CN disclosed
EP-4143181-A1 1-PYRAZINYLPYRAZOLYL-3-OXYALKYL ACIDS AND THEIR DERIVATIVES, AND THEIR USE FOR CONTROL OF UNDESIRED PLANT GROWTH Bayer Aktiengesellschaft (DE) 2023-03-08 EP disclosed
US-20220127256-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2022-04-28 US disclosed
EP-3299369-B1 PYRIDO-AZAHETERECYDIC COMPOUND AND PREPARATION METHOD AND USE THEREOF SHANGHAI INST MATERIA MEDICA CAS (CN) 2020-11-11 EP disclosed
US-10710996-B2 Pyrido-azaheterecydic compound and preparation method and use thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2020-07-14 US disclosed
US-20190201404-A1 THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SERVIER LAB (FR) 2019-07-04 US disclosed
US-20120220562-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2012-08-30 US disclosed
WO-2012116257-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. (US) 2012-08-30 WO disclosed
WO-2012051361-A1 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2012-04-19 WO disclosed
US-20120004196-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2012-01-05 US disclosed
US-20110282090-A1 PROCESS FOR PREPARING BORONIC ACIDS AND ESTERS IN THE PRESENCE OF MAGNESIUM METAL UNIVERSITE DE NICE SOPHIA ANTIPOLIS (FR) 2011-11-17 US disclosed
US-20110282090-A1 PROCESS FOR PREPARING BORONIC ACIDS AND ESTERS IN THE PRESENCE OF MAGNESIUM METAL UNIVERSITE DE NICE SOPHIA ANTIPOLIS (FR) 2011-11-17 US disclosed
US-20110207699-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2011-08-25 US disclosed
WO-2010055245-A2 PROCESS FOR PREPARING BORONIC ACIDS AND ESTERS IN THE PRESENCE OF MAGNESIUM METAL UNIVERSITE DE NICE - SOPHIA ANTIPOLIS (FR) 2010-05-20 WO disclosed
US-7329668-B2 Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same BRISTOL-MYERS SQUIBB COMPANY (US) 2008-02-12 US disclosed
US-7329668-B2 Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same BRISTOL-MYERS SQUIBB COMPANY (US) 2008-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230285378-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS LPL 1419/4885LIPG 768/4885ROCK1 2335/4885
US-20110282090-A1 PROCESS FOR PREPARING BORONIC ACIDS AND ESTERS IN THE PRESENCE OF MAGNESIUM METAL ME1, MEN1, CYP2B6 LPL 4602/4885LIPG 3893/4885ROCK1 3988/4885
US-20230167088-A1 1-PYRAZINYLPYRAZOLYL-3-OXYALKYL ACIDS AND THEIR DERIVATIVES, AND THEIR USE FOR CONTROL OF UNDESIRED PLANT GROWTH AGPS, CBR3, HPD LPL 4094/4885LIPG 2976/4885ROCK1 1851/4885
US-20120220562-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS LPL 1419/4885LIPG 768/4885ROCK1 2335/4885
US-20110207699-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS LPL 1419/4885LIPG 768/4885ROCK1 2335/4885
US-20190201404-A1 THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM TYMS, TYMP, TPX2 LPL 4515/4885LIPG 4399/4885ROCK1 3408/4885
US-20220127256-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 LPL 2221/4885LIPG 2618/4885ROCK1 1013/4885
US-20240228478-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 LPL 2221/4885LIPG 2618/4885ROCK1 1013/4885
US-20120004196-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS LPL 1419/4885LIPG 768/4885ROCK1 2335/4885
US-10710996-B2 Pyrido-azaheterecydic compound and preparation method and use thereof MET, MERTK, DMPK LPL 3586/4885LIPG 3670/4885ROCK1 702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.